DRTS
Alpha Tau Medical Ltd.
Healthcare — Biotechnology
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Price History
Fundamentals
| Market Cap | $1.14B |
| P/E Ratio (TTM) | - |
| Forward P/E | -24.56 |
| EPS (TTM) | $-0.67 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -90.51% |
| Debt/Equity | 20.68 |
| Recommendation | None |
| Analyst Target | $14.20 |
| Analysts | 5 |
| Next Earnings | May 18, 2026 |
| Indexes | - |
Technical Indicators
| RSI (14) | 81.3 |
| Beta | 1.20 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $13.06 |
| 52-Week Low | $2.87 |
| 50-Day Avg | $9.57 |
| 200-Day Avg | $6.62 |
| Avg Volume | 929.6K |
| Volume | 665.7K |
Performance Analysis
BEARISHDRTS is flashing more cautionary signals — investors should monitor closely.
Recent News
Last updated: Jul 02, 2026 13:06 UTC
Back to Screener Export Report